TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research September 13, 1996
TCL Archive PDF file includes 8-page February issue of Business & Regulatory Report. February 27, 2004
